Kainos Medicine, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kainos Medicine, Inc.
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
Following ABL Bio’s sizable Parkinson’s disease drug deal with Sanofi early this year, Korean bioventure Kainos Medicine is under the spotlight as its novel PD drug candidate enters Phase II in the US.
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.